ReviewClinical & developmental immunology2010
Overview of cellular immunotherapy for patients with glioblastoma.
Review in Clinical & developmental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Influence of Lipoxygenase Inhibition on Glioblastoma Cell Biology.International journal of molecular sciences · 2020Article
- Bioengineered recombinant vault nanoparticles coupled with NY-ESO-1 glioma-associated antigens induce maturation of native dendritic cells.Journal of neuro-oncology · 2020Article
- Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.Expert opinion on therapeutic targets · 2019Article
- Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts.Journal of visualized experiments : JoVE · 2018Article
- Advances in Immunotherapy for Glioblastoma Multiforme.Journal of immunology research · 2017Review
- Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma.Frontiers in pharmacology · 2017Review
- CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.Cancers · 2016Review
- Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.Oncoimmunology · 2016Article
- Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.Neuro-oncology · 2016Article
- Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5.Cell death & disease · 2015Article
- Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Article
- Prospects of immune checkpoint modulators in the treatment of glioblastoma.Nature reviews. Neurology · 2015Review
- Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide.Cancer immunology, immunotherapy : CII · 2015Article
- Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.Journal of neuro-oncology · 2015Article
- Immunotherapeutic advancements for glioblastoma.Frontiers in oncology · 2015Review
- The progress of immunotherapy for glioblastoma.Human vaccines & immunotherapeutics · 2015Review
- Vaccine therapies for patients with glioblastoma.Journal of neuro-oncology · 2014Review
- Clinical application of adoptive T cell therapy in solid tumors.Medical science monitor : international medical journal of experimental and clinical research · 2014Review
- Current Studies of Immunotherapy on Glioblastoma.Journal of neurology and neurosurgery · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours. Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM patients' prognosis remains very poor. Immunotherapy is one of the new promising therapeutic approaches that can specifically target tumour cells. Such an approach could also maintain long term antitumour responses without inducing neurologic defects. Since the past 25 years, adoptive and active immunotherapies using lymphokine-activated killer cells, cytotoxic T cells, tumour-infiltrating lymphocytes, autologous tumour cells, and dendritic cells have been tested in phase I/II clinical trials with HGG patients. This paper inventories these cellular immunotherapeutic strategies and discusses their efficacy, limits, and future perspectives for optimizing the treatment to achieve clinical benefits for GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.